JPMorgan Chase & Co. boosted its holdings in shares of Syros Pharmaceuticals (NASDAQ:SYRS) by 13.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 374,513 shares of the company’s stock after acquiring an additional 45,715 shares during the quarter. JPMorgan Chase & Co. owned 1.15% of Syros Pharmaceuticals worth $4,861,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of SYRS. Virtu Financial LLC bought a new stake in Syros Pharmaceuticals during the 4th quarter worth approximately $191,000. Two Sigma Advisers LP bought a new stake in Syros Pharmaceuticals during the 4th quarter worth approximately $105,000. Two Sigma Investments LP grew its holdings in Syros Pharmaceuticals by 80.3% during the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after acquiring an additional 9,439 shares during the last quarter. Adalta Capital Management LLC bought a new stake in Syros Pharmaceuticals during the 4th quarter worth approximately $111,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in Syros Pharmaceuticals by 76.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 76,740 shares of the company’s stock worth $997,000 after acquiring an additional 33,315 shares during the last quarter. 56.84% of the stock is currently owned by hedge funds and other institutional investors.
Syros Pharmaceuticals stock opened at $10.21 on Monday. Syros Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $24.38. The firm has a market cap of $332.62 million, a P/E ratio of -4.79 and a beta of -2.69.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, May 10th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.14). The company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $3.41 million. research analysts expect that Syros Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.
A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. BidaskClub upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd. Wedbush restated an “outperform” rating and issued a $13.00 price target (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 16th. Finally, HC Wainwright restated a “hold” rating and issued a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, March 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $21.13.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.